神经激肽-1受体抑制剂预防化疗分次给药所致恶心呕吐的临床观察

发布时间：2019-02-15 13:15

【摘要】：目的比较神经激肽-1受体抑制剂阿瑞匹坦三联方案与传统两联方案预防中高度催吐化疗方案分次给药所致恶心呕吐的疗效和安全性。方法对102例化疗患者前瞻性对照研究的数据进行中期分析,其中49例患者接受5-羟色胺-3受体抑制剂联合和托烷司琼两联止吐方案,53例患者接受神经激肽-1受体抑制剂阿瑞匹坦联合5-羟色胺-3受体抑制剂和托烷司琼的三联止吐方案;采用KaplanMeier曲线比较两组第一次呕吐发生时间,FLIE量表评价恶心呕吐生活质量;评价阿瑞匹坦的相关不良反应。结果 (1)主要终点指标三联方案CR率优于两联方案(P0.05)。次要指标AP和DP的CR率比较,差异均有统计学意义(均P0.05);(2)三联方案较两联方案的第一次呕吐发生时间晚(P0.05);每例FLIE量表大于108分表示对生活质量无影响,两组差异有统计学意义(P0.05)。(3)阿瑞匹坦的相关不良反应主要为上腹胀痛或便秘。结论三联止吐方案在中高度催吐性化疗方案分次用药所致恶心呕吐防治中疗效较好,安全可耐受。
[Abstract]:Objective to compare the efficacy and safety of neurokinin-1 receptor inhibitor Aripitan triple regimen and traditional two-regimen in the prevention of nausea and vomiting induced by moderate and high degree of emetic chemotherapy. Methods the data of 102 patients with chemotherapy were analyzed in a prospective controlled study. 49 patients were treated with 5-hydroxytryptamine 3 receptor inhibitor combined with tropisetron. 53 patients were treated with the triple antiemetic regimen of neurokinin-1 receptor inhibitor Aripitan combined with 5-hydroxytryptamine 3 receptor inhibitor and tropisetron. KaplanMeier curve was used to compare the time of first vomiting, FLIE scale was used to evaluate the quality of life of nausea and vomiting, and the related adverse reactions of aripitan were evaluated. Results (1) the CR rate of the triple regimen was better than that of the two schemes (P0.05). The CR rate of AP and DP were significantly different (P0.05); (2). The time of first vomiting in triple regimen was later than that in two groups (P0.05). There was no significant difference in quality of life between the two groups (P0.05). (3). The related adverse reactions of Arepitan were epigastric flatulence or constipation. Conclusion the triple antiemetic regimen is safe and tolerable in the prevention and treatment of nausea and vomiting caused by the moderate and high degree of emetic chemotherapy.
【作者单位】：鄂尔多斯市中心医院肿瘤科;
【分类号】：R730.53

【相似文献】